Market Cap
$1.1B
TNDM
TANDEM DIABETES CARE INC
$16.68 ▲ +1.09%
Prev close $16.50Market cap$1.1B
ConsensusBuy
12-mo target$28.35 (+70.0%)
▲ Bullish
Analyst conviction 6/10
27 New Institutional Positions19 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on TNDM right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Buy (62%)
Inst. Holders
50 funds
Inst. Value
$909.3M
Inst. Activity
27 buys / 19 sells
Social Sentiment
59° Warm
SEC Reports
3
Price chart 30d -18.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 short_volume
Short Volume: TNDM — 68.8% short (0.5M / 0.8M)
Short: 535,475 | Exempt: 397 | TRF Vol: 778,403 | Short Ratio: 68.8% | Off-exchange volume (dark poo
Aug 15, 2026 Insider
Sheridan John F surrendered for taxes 3,044 shares
PRESIDENT & CEO @ $22.72 ($69.2K)
Aug 15, 2026 Insider
Sheridan John F acquired via exercise 9,934 shares
PRESIDENT & CEO
Aug 15, 2026 Insider
Sheridan John F surrendered for taxes 5,055 shares
PRESIDENT & CEO @ $22.72 ($114.8K)
Jun 30, 2026 Inst.
JENNISON ASSOCIATES LLC — ADD
2,331,429 shares ($35.2M)
Jun 30, 2026 Inst.
Jun 11, 2026 SEC JACOBS LEVY EQUITY MANAGEMENT, — ADD
2,006,429 shares ($30.3M)
During Q3 2025, institutional activity in TNDM was mixed with 3 buyers adding $4.6M net and 6 sellers reducing holdings
INST-CLUSTER — Impact 5/10
Tandem Diabetes terminated EVP and Chief Commercial Officer Mark Novara without cause, effective May 18, 2026. The compa
8-K — Impact 3/10
Analyst ratings buy % +31.9%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
62% rate it Buy or better · 29 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 30, 2026 | Citigroup | MAINTAIN | Neutral | 55% |
| Sep 24, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Aug 21, 2026 | William Blair | INITIATE | Outperform | 51% |
| Aug 7, 2026 | Citigroup | MAINTAIN | Neutral | 55% |
| Aug 7, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Jul 15, 2026 | Mizuho | MAINTAIN | Neutral | 52% |
| Jun 23, 2026 | Deutsche Bank | INITIATE | Hold | 58% |
| Jun 1, 2026 | Wells Fargo | UPGRADE | Overweight | 54% |
| May 28, 2026 | Citigroup | MAINTAIN | Neutral | 55% |
| May 18, 2026 | B of A Securities | MAINTAIN | Neutral | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 7 | 11 | 11 | 0 | 0 | 62% | |
| Aug 1, 2026 | 6 | 11 | 11 | 0 | 0 | 61% | |
| Jul 1, 2026 | 6 | 11 | 12 | 0 | 0 | 59% | |
| Jun 1, 2026 | 6 | 11 | 12 | 0 | 0 | 59% | |
| May 1, 2026 | 6 | 11 | 12 | 0 | 0 | 59% | |
| Apr 1, 2026 | 6 | 11 | 12 | 0 | 0 | 59% | |
| Mar 1, 2026 | 6 | 9 | 15 | 0 | 0 | 50% | |
| Feb 1, 2026 | 6 | 8 | 15 | 1 | 0 | 47% |
Price targets
Where 20 covering analysts think TNDM trades over the next 12 months.
$28.35 +70.0% upside Strong Buy
Current$16.68 Low$18.00 Median$26.50 High$50.00 20 analysts
$18.00$50.00
Analyst rating Buy· 2.0/5 as of Oct 2, 2026
Social media sentiment mood +20.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
59°
Warm
BearishNeutralBullish
Recent posts
$1.2M yolo into $TNDM (Tandem Diabetes)
▲ 1 · 💬 9· ⚡ 0.5
886k in on TNDM!
▲ 1 · 💬 6· ⚡ 0.5
Tandem Diabetes ($TNDM) 10x play or getting bought out privately in the next few years ($825k bet)
▲ 1 · 💬 0· ⚡ 0.5
Tandem Diabetes ($TNDM) 10x play or getting bought out privately in the next few years ($825k bet)
▲ 1 · 💬 0· ⚡ 0.5
Tandem Diabetes ($TNDM) 10x play or getting bought out privately in the next few years ($825k bet)
▲ 1 · 💬 0· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
3 SEC filing reports analyzed · 0 bullish, 0 bearish, 1 mixed, 2 neutral · avg impact 3.7/10.
MIXEDINST-CLUSTER5/10
During Q3 2025, institutional activity in TNDM was mixed with 3 buyers adding $4.6M net and 6 seller
Jun 11, 2026
NEUTRAL8-K3/10
Tandem Diabetes terminated EVP and Chief Commercial Officer Mark Novara without cause, effective May
May 15, 2026
NEUTRALDEFA14A3/10
Tandem Diabetes Care filed a definitive additional proxy statement (DEFA14A) for an upcoming shareho
Apr 7, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 29, 2026
short_volume
Short Volume: TNDM — 68.8% short (0.5M / 0.8M)
Short: 535,475 | Exempt: 397 | TRF Vol: 778,403 | Short Ratio: 68.8% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
short_volume
Short Volume: TNDM — 73.5% short (0.8M / 1.1M)
Short: 826,166 | Exempt: 1,512 | TRF Vol: 1,124,110 | Short Ratio: 73.5% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: TNDM — 60.7% short (0.6M / 1.0M)
Short: 616,561 | Exempt: 110 | TRF Vol: 1,015,749 | Short Ratio: 60.7% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: TNDM — 67.0% short (0.9M / 1.3M)
Short: 876,869 | Exempt: 1,323 | TRF Vol: 1,309,500 | Short Ratio: 67.0% | Off-exchange volume (dark pool + OTC)
Sep 21, 2026
short_volume
Short Volume: TNDM — 57.6% short (0.5M / 0.8M)
Short: 453,310 | Exempt: 0 | TRF Vol: 787,292 | Short Ratio: 57.6% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.24 | $-0.36–$-0.16 | 21.9% | +0.0% | 3↑ 12↓ | $0.3B | 19 |
| Next Q | $0.18 | $0.02–$0.32 | 1882.0% | +0.0% | 12↑ 5↓ | $0.3B | 19 |
| Current FY | $-0.67 | $-0.91–$-0.45 | 74.1% | +0.0% | 11↑ 7↓ | $1.1B | 20 |
| Next FY | $0.17 | $-0.30–$0.57 | 125.6% | +0.0% | 12↑ 4↓ | $1.2B | 20 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.242 | — |
| 7d ago | $-0.242 | — |
| 30d ago | $-0.242 | — |
| 60d ago | $-0.180 | -0.063 |
| 90d ago | $-0.198 | -0.044 |
Institutional ownership
Which big funds own TNDM (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $909.3M total value (60,243,892 shares) as of 2026-Q2. Top holders: BlackRock,, UBS, VANGUARD. Net buying activity: 27 institutions added/increased vs 19 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 11,583,125 | $174.8M | 19.2% | — |
| UBS Group AG | 5,178,570 | $78.1M | 8.6% | TRIM -44.0% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4,299,667 | $64.9M | 7.1% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,096,536 | $46.7M | 5.1% | — |
| STATE STREET CORP | 2,851,646 | $43.0M | 4.7% | — |
| JENNISON ASSOCIATES LLC | 2,331,429 | $35.2M | 3.9% | ADD +40.6% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 2,006,429 | $30.3M | 3.3% | ADD +31.7% |
| Freestone Grove Partners LP | 1,866,134 | $28.2M | 3.1% | ADD +40.2% |
| GEODE CAPITAL MANAGEMENT, LLC | 1,800,797 | $27.2M | 3.0% | — |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1,786,996 | $27.0M | 3.0% | ADD +43.1% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| JENNISON ASSOCIATES LLC | ADD | 1,658,448 | 2,331,429 | +40.6% | $35.2M |
| JACOBS LEVY EQUITY MANAGEMENT, INC | ADD | 1,523,946 | 2,006,429 | +31.7% | $30.3M |
| Freestone Grove Partners LP | ADD | 1,330,742 | 1,866,134 | +40.2% | $28.2M |
| MILLENNIUM MANAGEMENT LLC | ADD | 761,672 | 1,311,739 | +72.2% | $19.8M |
| Woodline Partners LP | NEW | — | 1,307,439 | — | $19.7M |
| UBS Group AG | TRIM | 2,047,801 | 1,146,580 | -44.0% | $17.3M |
| FMR LLC | ADD | 714,011 | 976,432 | +36.8% | $14.7M |
| ROYCE & ASSOCIATES LP | ADD | 696,590 | 900,590 | +29.3% | $13.6M |
| GOLDMAN SACHS GROUP INC | TRIM | 2,218,922 | 862,301 | -61.1% | $13.0M |
| Verition Fund Management LLC | DOUBLED | 107,119 | 700,000 | +553.5% | $10.6M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
16 insiders, 50 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 15, 2026 | Sheridan John F | PRESIDENT & CEO | TAX W/H | 3,044 | $22.72 | $69.2K |
| Aug 15, 2026 | Sheridan John F | PRESIDENT & CEO | EXERCISE | 9,934 | — | — |
| Aug 15, 2026 | Sheridan John F | PRESIDENT & CEO | TAX W/H | 5,055 | $22.72 | $114.8K |
| Aug 15, 2026 | Sheridan John F | PRESIDENT & CEO | EXERCISE | 5,982 | — | — |
| Aug 15, 2026 | Hansen Shannon Marie | EVP & Chief Legal Officer | EXERCISE | 1,917 | — | — |
| Aug 15, 2026 | Hansen Shannon Marie | EVP & Chief Legal Officer | TAX W/H | 559 | $22.72 | $12.7K |
| Aug 15, 2026 | Gasser Elizabeth Anne | EVP, Chief Strategy Officer | EXERCISE | 1,917 | — | — |
| Aug 15, 2026 | Hansen Shannon Marie | EVP & Chief Legal Officer | EXERCISE | 1,097 | — | — |
| Aug 15, 2026 | Kyrillos Jean-Claude | EVP & Chief Operating Officer | TAX W/H | 535 | $22.72 | $12.2K |
| Aug 15, 2026 | Vosseller Leigh | EVP & CHIEF FINANCIAL OFFICER | TAX W/H | 537 | $22.72 | $12.2K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for TNDM.
Shares short
12,474,385
Settlement Sep 15, 2026
Change vs prior
+6.1%
Semi-monthly cycle
Days to cover
7.9
At avg daily volume
Of shares outstanding
≈17.9%
Estimate — not % of float
All TNDM filing & press-release reports (3)
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 15, 2026
- DEFA14A reportApr 7, 2026